{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T14:22:17Z","timestamp":1768400537270,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T00:00:00Z","timestamp":1544486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s12072-018-9915-5","type":"journal-article","created":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T14:16:55Z","timestamp":1544537815000},"page":"103-109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?"],"prefix":"10.1007","volume":"13","author":[{"given":"Tatsuo","family":"Kanda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George K. K.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lai","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiko","family":"Moriyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Lung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaaeldin","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cosmas Rinaldi Adithya","family":"Lesmana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Sollano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankur","family":"Jindal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barjesh Chander","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeed S.","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Kadir","family":"Dokmeci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Mamun-Al-Mahtab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geofferey W.","family":"McCaughan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jafri","family":"Wasim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darrell H. G.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Yokosuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiv Kumar","family":"Sarin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Omata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,11]]},"reference":[{"key":"9915_CR1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s12072-010-9193-3","volume":"4","author":"T Kanda","year":"2010","unstructured":"Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol Int 2010;4:548\u2013561","journal-title":"Hepatol Int"},{"key":"9915_CR2","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s12072-012-9342-y","volume":"6","author":"M Omata","year":"2012","unstructured":"Omata M, Kanda T, Yu ML, Yokosuka O, Lim SG, Jafri W, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012;6:409\u2013435","journal-title":"Hepatol Int"},{"key":"9915_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/00000441-200303000-00006","volume":"325","author":"MJ Mayo","year":"2003","unstructured":"Mayo MJ. Extrahepatic manifestations of hepatitis C infection. Extrahepatic manifestations of hepatitis C infection. Am J Med Sci 2003;325:135\u2013148","journal-title":"Am J Med Sci"},{"key":"9915_CR4","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/ki.2009.247","volume":"76","author":"ED Charles","year":"2009","unstructured":"Charles ED, Dustin LB. Hepatitis C virus-induced cryoglobulinemia. Kidney Int 2009;76:818\u2013824","journal-title":"Kidney Int"},{"key":"9915_CR5","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/039139881203500901","volume":"35","author":"F Fabrizi","year":"2012","unstructured":"Fabrizi F, Dixit V, Martin P, Messa P. The evidence-based epidemiology of HCV-associated kidney disease. Int J Artif Organs 2012;35:621\u2013628","journal-title":"Int J Artif Organs"},{"key":"9915_CR6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/hep.1840180202","volume":"18","author":"S Takano","year":"1993","unstructured":"Takano S, Omata M, Ohto M, Satomura Y. Prospective assessment of donor blood screening for antibody to hepatitis C virus and high-titer antibody to HBcAg as a means of preventing posttransfusion hepatitis. Hepatology 1993;18:235\u2013239","journal-title":"Hepatology"},{"key":"9915_CR7","doi-asserted-by":"publisher","first-page":"958","DOI":"10.7326\/0003-4819-112-12-958","volume":"112","author":"JB Zeldis","year":"1990","unstructured":"Zeldis JB, Depner TA, Kuramoto IK, Gish RG, Holland PV. The prevalence of hepatitis C virus antibodies among hemodialysis patients. Ann Intern Med 1990;112:958\u2013960","journal-title":"Ann Intern Med"},{"key":"9915_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/0168-8278(95)80307-6","volume":"23","author":"K Okuda","year":"1995","unstructured":"Okuda K, Hayashi H, Kobayashi S, Irie Y. Mode of hepatitis C infection not associated with blood transfusion among chronic hemodialysis patients. J Hepatol 1995;23:28\u201331","journal-title":"J Hepatol"},{"key":"9915_CR9","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.3748\/wjg.v10.i15.2209","volume":"10","author":"K Okuda","year":"2004","unstructured":"Okuda K, Yokosuka O. Natural history of chronic hepatitis C in patients on hemodialysis: case control study with 4\u201323\u00a0years of follow-up. World J Gastroenterol 2004;10:2209\u20132212","journal-title":"World J Gastroenterol"},{"key":"9915_CR10","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s12072-011-9284-9","volume":"6","author":"SK Satapathy","year":"2012","unstructured":"Satapathy SK, Lingisetty CS, Williams S. Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection. Hepatol Int 2012;6:369\u2013378","journal-title":"Hepatol Int"},{"key":"9915_CR11","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1111\/liv.13672","volume":"38","author":"AA Butt","year":"2018","unstructured":"Butt AA, Ren Y, Puenpatom A, Arduino JM, Kumar R, Abou-Samra AB. HCV treatment initiation in persons with chronic kidney disease in the directly acting antiviral agents era: results from ERCHIVES. Liver Int 2018;38:1411\u20131417","journal-title":"Liver Int"},{"key":"9915_CR12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1159\/000445374","volume":"10","author":"R Sasaki","year":"2016","unstructured":"Sasaki R, Kanda T, Yasui S, Haga Y, Nakamura M, Yamato M, et al. Successful eradication of hepatitis C virus by interferon-free regimens in two patients with advanced liver fibrosis following kidney transplantation. Case Rep Gastroenterol 2016;10:248\u2013256","journal-title":"Case Rep Gastroenterol"},{"key":"9915_CR13","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/hep.29258","volume":"66","author":"V Saxena","year":"2017","unstructured":"Saxena V, Khungar V, Verna EC, Levitsky J, Brown RS, Hassan MA, et al. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: results from the HCV-TARGET study. Hepatology 2017;66:1090\u20131101","journal-title":"Hepatology"},{"issue":"3","key":"9915_CR14","first-page":"19","volume":"2013","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2012;2013(3):19\u201362","journal-title":"Kidney Int Suppl"},{"key":"9915_CR15","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s12072-016-9717-6","volume":"10","author":"M Omata","year":"2016","unstructured":"Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int 2016;10:702\u2013726","journal-title":"Hepatol Int"},{"key":"9915_CR16","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","volume":"386","author":"D Roth","year":"2015","unstructured":"Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H Jr, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015;386:1537\u20131545","journal-title":"Lancet"},{"key":"9915_CR17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S2468-1253(17)30116-4","volume":"2","author":"A Bruchfeld","year":"2017","unstructured":"Bruchfeld A, Roth D, Martin P, Nelson DR, Pol S, Londo\u00f1o MC, et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4\u20135 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol 2017;2:585\u2013594","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"9915_CR18","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1111\/liv.13727","volume":"38","author":"T Asselah","year":"2018","unstructured":"Asselah T, Reesink H, Gerstoft J, de Ledinghen V, Pockros PJ, Robertson M, et al. Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: a pooled analysis. Liver Int 2018;38:1583\u20131591","journal-title":"Liver Int"},{"key":"9915_CR19","unstructured":"AASLD-IDSA HCV guidance: recommendations for testing, managing, and treating hepatitis C. https:\/\/www.hcvguidelines.org . Accessed 18 June 2018"},{"key":"9915_CR20","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","volume":"377","author":"E Gane","year":"2017","unstructured":"Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Br\u00e4u N, Brown A, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med 2017;377:1448\u20131455","journal-title":"N Engl J Med"},{"key":"9915_CR21","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s00535-017-1396-0","volume":"53","author":"H Kumada","year":"2018","unstructured":"Kumada H, Watanabe T, Suzuki F, Ikeda K, Sato K, Toyoda H, et al. Efficacy and safety of glecaprevir\/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastroenterol 2018;53:566\u2013575","journal-title":"J Gastroenterol"},{"key":"9915_CR22","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/hepr.12851","volume":"47","author":"G Suda","year":"2017","unstructured":"Suda G, Nagasaka A, Yamamoto Y, Furuya K, Kumagai K, Kudo M, et al. Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment. Hepatol Res 2017;47:1127\u20131136","journal-title":"Hepatol Res"},{"key":"9915_CR23","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00535-016-1162-8","volume":"51","author":"G Suda","year":"2016","unstructured":"Suda G, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kobayashi T, et al. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. J Gastroenterol 2016;51:733\u2013740","journal-title":"J Gastroenterol"},{"key":"9915_CR24","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00535-016-1174-4","volume":"51","author":"H Toyoda","year":"2016","unstructured":"Toyoda H, Kumada T, Tada T, Takaguchi K, Ishikawa T, Tsuji K, et al. Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. J Gastroenterol 2016;51:741\u2013747","journal-title":"J Gastroenterol"},{"key":"9915_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00535-017-1353-y","volume":"53","author":"G Suda","year":"2018","unstructured":"Suda G, Furusyo N, Toyoda H, Kawakami Y, Ikeda H, Suzuki M, et al. Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan. J Gastroenterol 2018;53:119\u2013128","journal-title":"J Gastroenterol"},{"key":"9915_CR26","doi-asserted-by":"publisher","first-page":"418","DOI":"10.7150\/ijms.15519","volume":"13","author":"T Kanda","year":"2016","unstructured":"Kanda T, Yasui S, Nakamura M, Suzuki E, Arai M, Haga Y, et al. Daclatasvir plus asunaprevir treatment for real-world HCV genotype 1-infected patients in Japan. Int J Med Sci 2016;13:418\u2013423","journal-title":"Int J Med Sci"},{"key":"9915_CR27","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1007\/s10620-018-4979-6","volume":"63","author":"S Taneja","year":"2018","unstructured":"Taneja S, Duseja A, De A, Mehta M, Ramachandran R, Kumar V, et al. Low-dose sofosbuvir is safe and effective in treating chronic hepatitis C in patients with severe renal impairment or end-stage renal disease. Dig Dis Sci 2018;63:1334\u20131340","journal-title":"Dig Dis Sci"},{"key":"9915_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13863","author":"M Kumar","year":"2018","unstructured":"Kumar M, Nayak SL, Gupta E, Kataria A, Sarin SK. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease. Liver Int 2018. https:\/\/doi.org\/10.1111\/liv.13863 (Epub ahead of print)","journal-title":"Liver Int."},{"key":"9915_CR29","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/hepr.13056","volume":"48","author":"T Sho","year":"2018","unstructured":"Sho T, Suda G, Nagasaka A, Yamamoto Y, Furuya K, Kumagai K, et al. Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction. Hepatol Res 2018;48:529\u2013538","journal-title":"Hepatol Res"},{"key":"9915_CR30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s12072-018-9859-9","volume":"12","author":"T Okubo","year":"2018","unstructured":"Okubo T, Atsukawa M, Tsubota A, Toyoda H, Shimada N, Abe H, et al. Efficacy and safety of ledipasvir\/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment. Hepatol Int 2018;12:133\u2013142","journal-title":"Hepatol Int"},{"key":"9915_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/nep.13222","author":"A Goel","year":"2018","unstructured":"Goel A, Bhadauria DS, Kaul A, Verma P, Mehrotra M, Gupta A, et al. Daclatasvir and reduced-dose sofosbuvir: an effective and pangenotypic treatment for hepatitis C in patients with eGFR < 30 ml\/min. Nephrology (Carlton). 2018. https:\/\/doi.org\/10.1111\/nep.13222 (Epub ahead of print)","journal-title":"Nephrology (Carlton)"},{"key":"9915_CR32","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol 2018;69:461\u2013511","journal-title":"J Hepatol"},{"key":"9915_CR33","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1055\/s-0033-1363965","volume":"64","author":"H Sharifi","year":"2014","unstructured":"Sharifi H, Hasanloei MA, Mahmoudi J. Polypharmacy-induced drug\u2013drug interactions; threats to patient safety. Drug Res (Stuttg) 2014;64:633\u2013637","journal-title":"Drug Res (Stuttg)"},{"key":"9915_CR34","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/MNH.0000000000000270","volume":"25","author":"SD Fraser","year":"2016","unstructured":"Fraser SD, Taal MW. Multimorbidity in people with chronic kidney disease: implications for outcomes and treatment. Curr Opin Nephrol Hypertens 2016;25:465\u2013472","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"9915_CR35","unstructured":"University of Liverpool. HEP drug interactions. http:\/\/www.hep-druginteractions.org . Accessed 7 Aug 2018"},{"issue":"suppl","key":"9915_CR36","doi-asserted-by":"publisher","first-page":"A1763","DOI":"10.1016\/S0735-1097(18)32304-0","volume":"71","author":"P Kwo","year":"2018","unstructured":"Kwo P, Jones P, Barcomb L, Gathe J Jr, Yu Y, Dylla D, et al. Safety and efficacy of statin management during glecaprevir\/pibrentasvir treatment for chronic hepatitis C. J Am Coll Cardiol 2018;71(suppl):A1763","journal-title":"J Am Coll Cardiol"},{"key":"9915_CR37","unstructured":"Coghlan M. Hepatitis C direct-acting anti-viral treatment options in patients with epilepsy. A drug\u2013drug interaction dilemma in hepatitis C infection. In: AASLD liver meeting 2017: abstract final ID: 1583"},{"key":"9915_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jceh.2015.04.004","volume":"6","author":"A Arora","year":"2016","unstructured":"Arora A, Bansal N, Sharma P, Singla V, Gupta V, Tyagi P, et al. Hepatitis C virus infection in patients with end-stage renal disease: a study from a tertiary care centre in India. J Clin Exp Hepatol 2016;6:21\u201325","journal-title":"J Clin Exp Hepatol"},{"key":"9915_CR39","doi-asserted-by":"crossref","first-page":"16263","DOI":"10.18632\/oncotarget.24620","volume":"9","author":"T Kanda","year":"2018","unstructured":"Kanda T, Yasui S, Nakamura M, Nakamoto S, Takahashi K, Wu S, et al. Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse events. Oncotarget 2018;9:16263\u201316270","journal-title":"Oncotarget"},{"key":"9915_CR40","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1111\/jvh.12937","volume":"25","author":"JR Kramer","year":"2018","unstructured":"Kramer JR, Puenpatom A, Erickson K, Cao Y, Smith D, El-Serag H, et al. Real-world effectiveness of elbasvir\/grazoprevir in HCV-infected patients in the US veterans affairs healthcare system. J Viral Hepat 2018;25:1270\u20131279","journal-title":"J Viral Hepat"},{"key":"9915_CR41","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/liv.13102","volume":"36","author":"V Saxena","year":"2016","unstructured":"Saxena V, Koraishy FM, Sise ME, Lim JK, Schmidt M, Chung RT, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int 2016;36:807\u2013816","journal-title":"Liver Int"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-018-9915-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-018-9915-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-018-9915-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T08:59:08Z","timestamp":1605603548000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-018-9915-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,11]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["9915"],"URL":"https:\/\/doi.org\/10.1007\/s12072-018-9915-5","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,11]]},"assertion":[{"value":"9 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Tatsuo Kanda received research grants from Merck Sharp and Dohme (MSD), Chugai Pharm and AbbVie. The founding sponsors played no role in the study design, data collection, analyses, interpretation, writing of the manuscript, or in the decision to publish the results. George K. K. Lau, Lai Wei, Mitsuhiko Moriyama, Ming-Lung Yu, Wang-Long Chuang, Alaaeldin Ibrahim, Cosmas Rinaldi Adithya Lesmana, Jose Sollano, Manoj Kumar, Ankur Jindal, Barjesh Chander Sharma, Saeed S. Hamid, A. Kadir Dokmeci, Mamun-Al-Mahtab, Geofferey W. McCaughan, Jafri Wasim, Darrell H. G. Crawford, Jia-Horng Kao, Osamu Yokosuka, Shiv Kumar Sarin, Masao Omata have declared that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not necessary, see above.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}